Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects. This clinical trial focuses on an innovative combination of two targeted inhibitors, Palbociclib and Bevacizumab, for their potential synergistic effects in addressing these challenging malignancies. Moreover, this study incorporates a molecular approach by considering Long Non-Coding RNAs (LncRNAs) as biomarkers. Initiating with a focus on colorectal cancer, the study aims to expand its scope to o

Trial Details

NCT ID
NCT06307249
Phase
PHASE1
Sponsor
Lebanese University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • SNP
  • Palbociclib 125mg
  • Bevacizumab
Locations (sample)
  • Tripoli, North Lebanon, Lebanon|34.43352,35.84415
  • Tripoli, North Lebanon, Lebanon|34.43352,35.84415

Key Eligibility Criteria

  • Individuals of white ethnicity.
  • Age between \> 18
  • Both males and females.
  • Diagnosis of selected cancer type (e.g., colorectal cancer, lung cancer, genitourinary cancers, breast cancer).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →